KLRC1 and COVID-19: As the defining features of these clusters enriched in COVID-19 positive patients are high expression of the inhibitory molecules NKG2A and KIR2DL1, we next aimed to assess if blocking these molecules could enhance the activity of NK cells derived from COVID-19 patients against SARS-CoV-2 infected cells.